Description
Description
Dolutegravir was developed by GlaxoSmithKline for the treatment of HIV-infected adults and children over 12 years old. Its product TIVICAY was approved in China in 2016 and was approved for children’s indications in China in 2019. As of the first half of 2021, ViiV Healthcare BV is the only manufacturer in the Chinese Dolutegravir market.
According to CRI’s market research, the sales of Dolutegravir in the Chinese market have had an upward trend from 2016 to 2020. Due to the advantages of Dolutegravir, such as good tolerability, drug resistance, and convenience of taking drugs, its sales in the Chinese market have grown rapidly, from CNY0.2 million in 2016 to CNY3.14 million in 2017, with an annual growth rate of 1392.89%. In 2020, sales of Dolutegravir fell by 12.92%. The main reason for a decline in its sales is that the COVID-19 epidemic has impacted the hospital’s overall diagnosis and treatment business. Dolutegravir has a CAGR of 166.14% from 2016 to 2020.
CRI predicts the sales of Dolutegravir will increase from 2021 to 2025 with the increase in the number of AIDS patients. The number of surviving HIV-infected people in China increased from 958,000 in 2019 to 1.045 million in 2020, with a growth rate of 9%. The number of new infections shows an increasing trend. Therefore, sales of Dolutegravir used to treat HIV infection will continue to increase. In addition, with the effective alleviation of the COVID-19 epidemic, the sales of Dolutegravir will have a restorative growth from 2021 to 2025.
Topics Covered:
-The impact of COVID-19 on China’s Dolutegravir market
– Sales value of China’s Dolutegravir 2016-2020
– Competitive landscape of China’s Dolutegravir market
– Prices of Dolutegravir in China
– Prices of Dolutegravir in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Dolutegravir market
– Prospect of China’s Dolutegravir market from 2021 to 2025
Table of Contents
Table of Contents
1 Relevant Concept of Dolutegravir
1.1 Indications for Dolutegravir
1.2 Development of Dolutegravir in China
1.3 Governmental Approval of Dolutegravir in China
1.4 The Impact of COVID-19 on Dolutegravir sales in China
2 Sales of Dolutegravir in China, 2016-2020
2.1 Sales Value of Dolutegravir
2.1.1 Overall Sales Value
2.1.2 Sales Value by Regions
2.2 Sales Volume of Dolutegravir
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Regions
2.3 Sales of Dolutegravir by Dosage Form in China, 2016-2020
2.3.1 Tablets
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Dolutegravir Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Dolutegravir Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 ViiV Healthcare BV
3.2.1 Enterprise Profile
3.2.2 Sales of TIVICAY (ViiV Healthcare BV’s Dolutegravir) in China
3.3 Analysis of Other Enterprises
4 Prices of Dolutegravir for Different Manufacturers in China, 2020-2021
4.1 ViiV Healthcare BV (TIVICAY)
4.2 Analysis of Other Enterprises
5 Prospect of Chinese Dolutegravir Market, 2021-2025
5.1 Influential Factors of Chinese Dolutegravir Market Development
5.1.1 The Impact of COVID-19 on Chinese Dolutegravir Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information About Dolutegravir Tablets Registration in China
Chart Sales Value of Dolutegravir Tablets over the World
Chart Sales Value of Dolutegravir Tablets in China, 2016-2020
Chart Sales Value of Dolutegravir Tablets in China by Regions, 2016-2020
Chart Sales Volume of Dolutegravir Tablets in China, 2016-2020
Chart Sales Volume of Dolutegravir Tablets in China by Regions, 2016-2020
Chart Market Share by Sales Value of Top Dolutegravir Manufacturers in China, 2016-2020
Chart Sales Value and Volume of TIVICAY in China, 2016-2020
Chart Referential Prices of TIVICAY in China by Regions, 2020-2021
Chart Forecast on Sales Value of Dolutegravir in China, 2021-2025
Chart Forecast on Sales Volume of Dolutegravir in China, 2021-2025
